What is the relationship between PT-141 (Bremelanotide) and subsequent cough?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

PT-141 (bremelanotide) can sometimes cause coughing as a side effect, though it's not among the most commonly reported reactions, and if you're experiencing a cough after using PT-141, you should consider temporarily discontinuing use and consulting with your healthcare provider. The cough may be related to an allergic or inflammatory response to the medication. According to the most recent study 1, the safety profile of bremelanotide is mostly mild to moderate, with the most common adverse events being nausea, flushing, and headache. However, coughing is not explicitly mentioned as a common side effect in this study.

Possible Mechanism and Management

The coughing mechanism might be related to PT-141's action on melanocortin receptors, which are present in various tissues including the respiratory tract, as suggested by the study on the neurobiology of bremelanotide 2. Some users find that proper injection technique (ensuring the medication is administered subcutaneously rather than intramuscularly) and staying well-hydrated before and after administration may help reduce side effects.

Recommendations for Use

PT-141 is typically administered via subcutaneous injection at doses of 1.75 mg approximately 45 minutes before sexual activity, and should not be used more than once in 24 hours or more than 8 times per month, as recommended by the study on the safety profile of bremelanotide 1. If the cough persists or is severe, this could indicate a more serious reaction requiring immediate medical attention, especially if accompanied by difficulty breathing, chest tightness, or facial swelling.

Key Considerations

  • The most common adverse events associated with bremelanotide are nausea, flushing, and headache, as reported in the study on the safety profile of bremelanotide 1.
  • Bremelanotide has been shown to significantly improve sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder, as demonstrated in the studies on the efficacy of bremelanotide 3, 4.
  • Proper use and administration of PT-141, as well as monitoring for potential side effects, are crucial for minimizing risks and maximizing benefits.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.